Almost all healthcare associations alongside medical laboratory research centers around the globe are on the hunt to find a promising vaccine with an optimal effectiveness for all age groups in our diversified community.
Before we even knew it, a worldwide respiratory disease with high spread ability was beginning to appear in several regions and countries. This pandemic has thrown the health system a lot of unexpected complications and assigned heavy responsibilities to all healthcare workers, practitioners, and specialists in the world within a very short period of time. The challenge arises with being able to increase the vaccine’s success rate in order to help a maximum number of people, within a minimum amount of time, especially with the huge rise of daily positive coronavirus cases locally, nationally and internationally.
During this past year, preventing societies from further risk and difficulties regarding the COVID-19 pandemic, in addition to providing them with a beneficial and safe vaccine that will enhance their immune system has been a priority on a worldwide range.
According to the World Health Organization WHO, up to 172 countries and multiple vaccine candidates engaged in COVID-19 vaccine Global Access Facility. These economies are willing to support and participate in COVAX, a global initiative aimed at working with vaccine manufacturers to provide accessible, affordable, safe and effective vaccines on an international level.
More than 150 covid-19 vaccines are being developed worldwide. Six are in final, large-scale clinical trials. Governments have invested $10bn in them and are reckoned to have made forward purchases of about 4bn doses. But what do we know about these new vaccines? Are they as efficient as they appear on the news and on all social media platforms?
Let’s take a closer look at one of the final six vaccines, NOVAVAX, in order to understand more about how these forms of vaccines work.
In short, this vaccine is engineered with the genetic sequence of the coronavirus, as it employs novavax recombinant nanoparticle technology in order to generate antigen derived from the covid-19 spike (S) protein, and contains novavax’s saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. In July, it was awarded $1.6bn from the US’ Operation Warp speed and it has set hopes to produce up to two billion doses a year, to be able to fulfill the urgent and continuous needs for this vaccine.
Although the number of advocates for these vaccines is astoundingly increasing by the day, several health associations and organizations are still doubting the reliability of the vaccines and the sources due to the fact that they might be obliged to deliver information and new discoveries to the thirsty press.
Locally, more than 100,000 citizens in Lebanon have been diagnosed with the SARS-Cov2 virus and the numbers are still increasing to the day. Health minister Hamad Hassan announced that the coronavirus vaccine would be available as of the first quarter of 2021. Consequently, Lebanon is expected to be set for a good immunization in the beginning of the upcoming year if the vaccine is as efficacious as cited.
The final question is: If the WHO was about to announce an official vaccine to prevent covid-19 and induce the reduction of positive cases, would you personally trust the process and take the vaccine for it was conducted after accumulative and profound research and studies by numerous specialists? Or would you doubt the accuracy of the results and prefer not taking it for there might be political and economic factors affecting this discovery?
18 years old. Passionate about writing and longing to find justice in society someday.